Florian Tobias Alwin Kretz; Gerd Uwe Auffarth

doi:10.5384/sjovs.vol5i2p1-4

Authors

Florian Tobias Alwin Kretz International Vision Correction Research Centre (IVCRC), University of Heidelberg, Dept. Ophthalmology, Im Neuenheimer Feld 400, 69120 Heidelberg
Gerd Uwe Auffarth International Vision Correction Research Centre (IVCRC), University of Heidelberg, Dept. Ophthalmology, Im Neuenheimer Feld 400, 69120 Heidelberg

DOI:

https://doi.org/10.5384/sjovs.vol5i2p1-4

Keywords:

central retinal vein occlusion, cataract, macular edema,

Abstract

A 77 years old patient presented for cataract surgery. At first visit we found a cataract and hypertensive signs of the fundus. Six month later during pre-surgical examination a cystoid macular edema (CME) caused by central retinal vein occlusion (CRVO) was found. As the cataract had proceeded, we decided to perform a combined surgery with intravitreal application of a dexamethason implant. The biometry of the first visit was used for IOL calculation. The procedure was performed without complications. Pre-surgical BCVA [logMAR] increased from 0.3 to 0.1 ten days after surgery while the central retinal thickness decreased from 586µm to 353µm with a nearly complete disappearance of the CME. Cataract surgery in patients with CME after CRVO can be combined with an intravitreal dexamethason implant and so lead to a good visual rehabilitation. Further studies are needed to give better evidence of the effectivity and to predict the possible treatment duration.

Metrics

Metrics Loading ...

References

Ahmadabadi HF, M.M., Beheshtnejad H, Mirshahi A. (2010, Jun). Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification. J Cataract Refract Surg, 917-922.

Akinci A, B.C., Ozkilic E, Altinsoy A. (2009, Nov-Dec). Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract. Retina, 1432-1435.

Akinci A, M.O., Altınsoy A, Ozkılıc E. (2010). PHACOEMULSIFICATION WITH INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE INJECTION IN DIABETIC PATIENTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA AND CATARACT. Retina.

Campochiaro, P.A., Heier, J.S., Feiner, L., Gray, S., Saroj, N., Rundle, A.C., . . . Rubio, R.G. (2010). Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology, 117(6), 1102-1112 e1101. doi: 10.1016/j.ophtha.2010.02.021

Chun, D.W., Heier, J.S., Topping, T.M., Duker, J.S., & Bankert, J.M. (2006). A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology, 113(10), 1706-1712. doi: 10.1016/j.ophtha.2006.04.033

Coscas, G., Coscas, F., Zucchiatti, I., Glacet-Bernard, A., Soubrane, G., & Souied, E. (2011). SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex(R). European journal of ophthalmology, 21(5), 631-636. doi: 10.5301/EJO.2011.7428

Ding X, L.J., Hu X, Yu S, Pan J, Tang S. (2011, February). PROSPECTIVE STUDY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina.

Frampton, J.E. (2012). Ranibizumab: in diabetic macular oedema. Drugs, 72(4), 509-523. doi: 10.2165/11208410-000000000-00000

Haller, J.A., Bandello, F., Belfort, R.J., Blumenkranz, M.S., Gillies, M., Heier, J., . . . Group, O.G.S. (2010, Jun). Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology, 1134-1146.

Heier, J.S., Campochiaro, P.A., Yau, L., Li, Z., Saroj, N., Rubio, R.G., & Lai, P. (2012). Ranibizumab for Macular Edema Due to Retinal Vein Occlusions Long-term Follow-up in the HORIZON Trial. Ophthalmology. doi: 10.1016/j.ophtha.2011.12.005

Jonas JB, S.U., Schlichtenbrede F, Libondi T, Vossmerbaeumer U, von Baltz S. (2007, Dec). Intravitreal bevacizumab combined with cataract surgery for treatment of exudative macular degeneration. J Ocul Pharmacol Ther, 599-600.

Kim, N.R., Lee, H., Lee, E.S., Kim, J.H., Hong, S., Je Seong, G., & Kim, C.Y. (2010). Influence of Cataract on Time Domain and Spectral Domain Optical Coherence Tomography Retinal Nerve Fiber Layer Measurements. J Glaucoma. doi: 10.1097/IJG.0b013e31820277da

McCannel, C.A. (2011). Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina, 31(4), 654-661. doi: 10.1097/IAE.0b013e31820a67e4

Meyer, L.M., & Schonfeld, C.L. (2011a). Cystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant. Case Report Ophthalmol, 2(3), 319-322. doi: 10.1159/000332424

Meyer, L.M., & Schonfeld, C.L. (2011b). Fast Resolution of Recurrent Pronounced Macular Edema following Intravitreal Injection of Dexamethasone 0.7 mg. Case Report Ophthalmol, 2(2), 246-250. doi: 10.1159/000330665

Moshfeghi, A.A. (2011). Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Semin Ophthalmol, 26(3), 139-148. doi: 10.3109/08820538.2011.570847

Nguyen, Q.D., Brown, D.M., Marcus, D.M., Boyer, D.S., Patel, S., Feiner, L., . . . Ehrlich, J.S. (2012). Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. doi: 10.1016/j.ophtha.2011.12.039

Parodi, M.B., Iacono, P., Cascavilla, M., Zucchiatti, I., & Bandello, F. (2011). Compassionate use of dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion in a clinical setting. Acta Ophthalmol. doi: 10.1111/j.1755-3768.2011.02238.x

Rehak M, W.P. (2010, September). Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost, 1886-1894.

Sonoda Y, A.N., Shimura M, Sakamoto T. (2011, February). Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina, 290-297.

Thapa R, P.G., Bernstein PS. (2010, Aug). Demographic characteristics, patterns and risk factors for retinal vein occlusion in Nepal: a hospital-based case-control study. Clin Experiment Ophthalmol, 583-590.

Winterhalter, S., Ruokonen, P., van der Velden, K.H., Pleyer, U., & Joussen, A.M. (2011). [Intravitreal implants: drug carriers and carriers of hope?]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 108(3), 222-229. doi: 10.1007/s00347-010-2264-y

Wu L, A.J., Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J, & (PACORES), P.-A.C.R.S.G. (2008, Feb). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina, 212-219.

Yeh, W.S., Haller, J.A., Lanzetta, P., Kuppermann, B.D., Wong, T.Y., Mitchell, P., . . . Kowalski, J.W. (2012). Effect of the Duration of Macular Edema on Clinical Outcomes in Retinal Vein Occlusion Treated with Dexamethasone Intravitreal Implant. Ophthalmology. doi: 10.1016/j.ophtha.2011.12.028